

1016 *neoformans* via endocytotic and transcellular mechanisms that require Mpr1 and Annexin A2  
1017 (AnxA2).<sup>[18,69]</sup> Sustained EphA2 activation could weaken intercellular junctions thereby increase  
1018 paracellular permeability and boost further entry of *C. neoformans* along with excess fluid that  
1019 would lead to brain edema (indicated by dashed arrows).

1020 **S1\_Fig 1.** A chart representing the work-flow for the transcriptome analysis of human brain  
1021 endothelial cells challenged with *C. neoformans*.

1022 **S2\_Fig 2.** A Multi-Dimensional Scaling (MDS) plot for gene expression data. The MDS plot  
1023 shows the distance relationship (i.e. level of similarity) between the two sample treatment  
1024 groups based on gene expression. Data set #1 represents samples of human brain endothelial  
1025 cells treated with *C. neoformans* (HB1, HB2, HB3, indicated by circle). This data set was tightly  
1026 clustered and apart from untreated brain endothelia cells (B1, B2, B3, data set #2, indicated by  
1027 square). The data set #2 was clustered and separate from data set #1.

1028 **S3\_Fig 3.** Transcytosis assay revealed that the transmigration of *C. neoformans* is not affected  
1029 by knocking down ephrinA1 ligand in human brain endothelial cells. (A) Quantitative PCR  
1030 revealed that siRNA of ephrinA1 repressed the expression of ephrinA1 approximately 83%. (B)  
1031 Transcytosis assay demonstrated that *C. neoformans* could still migrate across brain endothelial  
1032 cells.

1033 **S1\_Table 1.** A list of randomly selected, differentially expressed genes from human brain  
1034 endothelial cells challenged with *C. neoformans* obtained by RNA-seq and validated by  
1035 quantitative reverse transcriptase PCR (qRT-PCR).

1036 **S2\_Table 2.** A list of primers used for quantitative reverse transcriptase PCR (qRT-PCR) and  
1037 the gene name associate with each set of primers (forward and reverse).

1038 **S1\_Movie.** Live-cell recording of HEK293T cells overexpressing EphA2 interacting with


1039 *C. neoformans* H99. Images are close-ups of 10X magnification. (A, C) Imaging shows EphA2  
1040 receptor (red), nuclei (blue), and H99 (green). (B, D) Bright-field imaging of A and C,  
1041 respectively.

1042 **S2\_Movie.** Live-cell recording: HEK293T cells transformed with an empty plasmid do not  
1043 interact with *C. neoformans*. In this recording HEK293T cells were not transformed with EphA2-  
1044 cDNA. Images are close-ups of 10X magnification. (A, C) Imaging shows H99 (green) and  
1045 nuclei (blue). (B, D) Bright-field imaging of A and C, respectively.

1046 **S3\_Movie.** Live-cell recording: HEK293T cells overexpressing EphA2 to do not engage  
1047 fluorescent beads. Images are close-ups of 10X magnification. (A, B) Imaging shows EphA2  
1048 receptor (red), nuclei (blue), and plastic bead (green). (C, D) Bright-field imaging of A and B,  
1049 respectively.


1050

S1\_ Fig 1




254x338mm (300 x 300 DPI)

S2\_Fig 2



254x338mm (300 x 300 DPI)

S3\_Fig 3



254x338mm (300 x 300 DPI)

S1\_Table 1

**Table 1.** A list of randomly selected, differentially-expressed genes from hBMECs challenged With *C. neoformans* obtained by RNA-seq and validated by quantitative reverse transcriptase PCR (qRT-PCR).

<b>Gene names</b>	<b>Fold-change (RNA-seq)</b>	<b>Fold-change (qPCR)</b>
STAB1 – stabillin-1	2.69	1.9
NPTX1 – neuronal pentraxins	4.42	9.15
EDNRA – receptor for endothelin-1	4.22	5.11
EDN1 – endothelin-1	2.47	N/A
END2 – endothelin-2	4.66	10.63
EEA1 – early endosome antigen-1	-1.55	-1.16
SRXN2 – sulfiredoxin-1	-2.33	-1.23
SIRT1 – NAD-dependent deacetylase sirtuin-1	-1.92	1.12
NRGE2 – growth factor (neuregulin)	1.97	2.5
GMFB – glial maturation factor	-2.42	1.05
Coorf10 – transcription factor	3.91	11.41
EFNA1 – ephrinA1	2.06	3.58

254x338mm (300 x 300 DPI)

S2\_Table 2

**Table 2.** Primers used for qRT-PCR.

Gene	gene name	Primer for real time PCR (5'-----3')	
		Forward primer	Reverse primer
EDN1	Endothelin-1	GAATCAGGGCTGAAGACATTATGGA	TGGTTTGCTTAGGTGTTCTCTGAAC
EDN2	Endothelin-2	CAGCCAGCGTCCTCATCTCATG	GAGCTGTCTGTTCAGGAGTGTCA
EDNRA	Receptor for endothelin-1	TATCAATGTATTTAAGCTGCTGGCTGG	CTGCTCTGTACCTGTCAACACTAAGA
EFNA1	Ephrin A1	AACAGTTCAAATCCAAGTCCGGA	GTACAGTATGTAAGTCTCCATGGCA
GMFB	Glial maturation factor	AACGACAACCTCGCTTCATTGTGTATA	CAAATACCTGGTTAGTTCAGCTGTCTG
NPTX1	Neuronal Pentraxins	AGGAGAGGGTCAAGATCGAGACC	CATATAGTTGGTCCGCAGTGGGAA
NGR2	Growth factor (neuregulin)	CAGATTATATTCCAAGAACGTGCCAGC	TGGAGCAGTGGTGAGAAGGAGAA
SIRT1	Sirtuin-1	TATATCCTGGACAATTCCAGCCATCTC	GTTGCAAGGAACCATGACACTGAA
SRXN1	Sulfiredoxin-1	GACACGATCCGGGAGGACC	CCCAAAGGAGTAGAAGTAGTCACTC
STAB1	Stabilin-1	TGTGTGCACGGAGTGTGCAA	CGGGCAGCTCTTGATCACAGT
EEA1	Early endosome antigen-1	AGCTCTTCAGAGGGTTTCATATGTCC	CCATGACCTGAGTCAATACCAGCAT
C10orf10	transcription factor	CATCACCGCACGTTTCAGTGG	ACTCCCCAAAAGCCAGTCCA
YWHAZ	tyrosine 3-monooxygenase	GAAAGGGATTGTCGATCAGTCACAAC	CCAGTCTGATAGGATGTGTGGTTGC

254x338mm (300 x 300 DPI)